Everyone listen up. I've posted quite a bit on this forum about MT2 and have "tested" the substance for years now. I want everyone to be aware of the following [
Melanotan II injection resulting in sys... [Clin Toxicol (Phila). 2012] - PubMed - NCBI]:
I've personally tested/witnessed high blood pressure spikes/hypertension with MT II. If you're researching this chem, I would advise you monitor blood pressure carefully and I would not advise taking it if you've had hypertension issues in the past.
What's key about the below is reported systemic toxicity, rhabdomyolysis (death of striated muscle cells), and renal (kidney) dysfunction. Yes, this guy may have OD'd on MT2 but you should be aware that extended use of this peptide may eventually cause problems in those areas.
I actually met a researcher who was studying MT2's effect on the melanocortin system with regard to causing behavioral and psychosocial changes. She wanted me to share my research (and prob M2 boner lol) but i'll leave that out from this write-up since it's not well-documented, a relatively new study, and distracting.
In late winter I would start a cycle of d1 .25mcg, d3, .5mcg, d4, .5mcg, d6 .5mcg (loading phase) with plenty of UV is synergistic and very effective. I would then maintain that every weekend with .5mcg and some play of course... you can guess what that is. My concern is when you get into taking it weekly for a year or so-- it's not really well documented how that impacts blood pressure, toxicity in the nervous system, kidneys, and striated muscle cells
over time.
So be careful with this one brothers. Stay informed. Research carefully before testing. --Liberate
Abstract
INTRODUCTION:
Melanotan products are currently purchased over the Internet and are designed to induce melanogenesis to create sunless tanning as well are used as sexual stimulants. We report a novel case of
systemic toxicity with sympathomimetic excess and
rhabdomyolysis after use of Melanotan II.
CASE REPORT:
A 39 year-old Caucasian male injected subcutaneously 6 mg of Melanotan II purchased over the Internet in an attempt to darken his skin during wintertime. This dose was six times the recommended starting dose per the patient. In the emergency department two hours post injection, he complained of diffuse body aches, sweating, and a sensation of anxiety. Vital signs included BP 151/85 mmHg, HR 130 bpm that peaked at 146 bpm, and temperature of 97.8°F. Physical exam demonstrated a restless and anxious appearing male with mydriasis, diaphoresis, tachycardia, and diffuse muscle tremors. Pertinent laboratory values were creatinine 2.25 mg/dL, CPK 1760 IU/L, troponin 0.23 ng/mL, WBC 19.1 k/***956;L. Urinalysis demonstrated 3 + blood with red cell casts but 0-2 RBC/hpf. Qualitative urine drug screen was negative for metabolites of cocaine and amphetamines but positive for opiates. The patient received benzodiazepines for agitation and anxiety and had improvement in his symptoms. He was admitted to the ICU and during hospitalization his CPK elevated to 17773 IU/L 12 hours later. He continued to receive intravenous fluids with sodium bicarbonate for rhabdomyolysis and his CPK decreased to 2622 IU/L with improvement of creatinine to 1.23 mg/dL upon discharge from the ICU after 3 days. The substance, which he injected, was analyzed via mass spectrometry and was confirmed to be Melanotan II when compared with an industry purchased standard sample.
DISCUSSION:
Melanotan products are purchased via the Internet and have three main formulations (Melanotan I, Melanotan II, and bremelanotide). Melanotan I increases melanogenesis and eumelanin content to produce sunless tanning. Melanotan II also increases skin pigmentation but also produces spontaneous penile erections and sexual stimulation. Bremelanotide is a variation of Melanotan II that is specifically designed for sexual stimulation. This unique case highlights the potential of systemic toxicity with sympathomimetic excess, rhabdomyolysis, and renal dysfunction from Melanotan II use.
CONCLUSION:
Melanotan II use resulted in systemic toxicity including apparent sympathomimetic symptoms, rhabdomyolysis, and renal dysfunction.
